Beam Therapeutics (BEAM) Current Deferred Revenue (2020 - 2026)

Beam Therapeutics (BEAM) has reported Current Deferred Revenue for 7 consecutive years, with $304000.0 the latest figure, recorded in Q1 2026.

• In Q1 2026, Current Deferred Revenue fell 99.64% year-over-year to $304000.0; the TTM figure through Mar 2026 stood at $304000.0 (down 99.64% YoY), while the FY2025 annual figure was $6.7 million, down 95.31% from the prior year.
• Current Deferred Revenue slipped to $304000.0 in Q1 2026 per BEAM's latest filing, from $6.7 million in the prior quarter.
• Across five years, Current Deferred Revenue topped out at $338.2 million in Q4 2022 and bottomed at $304000.0 in Q1 2026.
• Historically, Current Deferred Revenue has averaged $121.4 million across 5 years, with a median of $115.0 million in 2022.
• Annual changes were most pronounced in 2022 — Current Deferred Revenue surged 1147.09% — and 2026, when it tumbled 99.64%.
• Beam Therapeutics' Current Deferred Revenue stood at $338.2 million in 2022, then plunged by 47.19% to $178.6 million in 2023, then declined by 20.45% to $142.1 million in 2024, then tumbled by 95.31% to $6.7 million in 2025, then tumbled by 95.43% to $304000.0 in 2026.
• Business Quant data shows BEAM's Current Deferred Revenue at $304000.0 in Q1 2026, $6.7 million in Q4 2025, and $110.3 million in Q3 2025.